VCM
GBT

Versant Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Versant Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13
Closed – – 1640
2020
Q4 		$0 Hold
13
– – ﹤0.01% 1591
2020
Q3 		$0 Sell
13
-2
-13% -$127 ﹤0.01% 1573
2020
Q2 		$0 Hold
15
– – ﹤0.01% 1632
2020
Q1 		$0 Hold
15
– – ﹤0.01% 1798
2019
Q4 		$1K Hold
15
– – ﹤0.01% 1310
2019
Q3 		$0 Buy
+15
New +$782 ﹤0.01% 1667
2019
Q2 		– Sell
-6
Closed – – 1802
2019
Q1 		$0 Buy
+6
New +$295 ﹤0.01% 1802

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Versant Capital Management's GBT Position: Q1 2021 in Review

Versant Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 13 shares.

Versant Capital Management first reported a position in GBT in Q1 2019 and held it in 7 quarters. The position peaked at $1K in Q4 2019. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

  • Versant Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Versant Capital Management sold 13 Global Blood Therapeutics, Inc. shares in Q1 2021.
  • Versant Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2019 and held it in 7 quarters.
  • Versant Capital Management's Global Blood Therapeutics, Inc. position peaked at $1K in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on Versant Capital Management's 13F filing for Q1 2021, filed 27 Apr 2021.